Amisulpride

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Amisulpride

Examples of brand names: Solian [DE]

ATC code: N05AL05

Main use (for orientation): Schizophrenia

Documented research summary

A small phase I lipidomics study examined CBD added to several antipsychotics, including amisulpride. The abstract does not isolate a reliable amisulpride-specific pharmacokinetic/clinical harmful effect. Renal elimination makes CYP-only extrapolation inappropriate.

Uncertainties and limitations

Cell/animal models and uncontrolled observations cannot be directly applied to clinical dosing decisions.

Rare cannabinoids within the scope of 28 remain poorly documented where pair-specific findings are absent.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – clinical signals

Finding ID: B0327

Type of result: Clinical signals

Observation: Lipid changes with pooled antipsychotics were partly reversed by CBD; no established amisulpride-specific clinical effect in the abstract.

Mechanism: Exploratory pharmacodynamic lipidomics, not a measured pharmacokinetic interaction.

Study type: Phase I study, exploratory biomarker analysis; abstract

Context studied: 38 healthy participants, five arms; amisulpride 150 mg/day; after three days, CBD 800 mg/day added for six days.

Clinical interpretation: Clinical significance undetermined

Limitations and uncertainties: Small arms, pooled endpoints; full-text access failed. No weight/lipid-prevention or dosing recommendation.

Original sources for this finding: Alterations to sphingolipid metabolism from antipsychotic administration in healthy volunteers are restored following the use of cannabidiol. [CA_P_38950483]

References and access status

[C_LABEL_D0128] Amisulpride 200 mg Tablet, SmPC

Original source / bibliographic reference

Authors: Pharmaceutical company not separately entered in the source field; product / official product information identified by title and URL

Year: 2026

Source type: Product information / SmPC

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CA_P_38950483] Alterations to sphingolipid metabolism from antipsychotic administration in healthy volunteers are restored following the use of cannabidiol.

Original source / bibliographic reference

Authors: Jieu B, Sykorova EB, Rohleder C, Marcolini E, Hoffmann AE, Koethe D, Leweke FM, Couttas TA.

Year: 2024

Source type: Research Support, Non-U.S. Gov't; Clinical Trial, Phase I; Randomized Controlled Trial; Journal Article

DOI: 10.1016/j.psychres.2024.116005

PMID: 38950483

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility